Lifeline Biotechnologies' First Warning Retains Engineering Firm

RENO, Nev., Dec. 22, 2011 /PRNewswire/ -- Lifeline Biotechnologies, Inc., (OTC Market: LLBO) announces a new engineering contract with Synergy Technology, Inc. to focus on device value engineering.  Jim Holmes, CEO, says, "This relationship will result in an updated design for our breast testing device package for a current, more cost effective technology while maintaining the product integrity from our previous clinical trials.  We expect this will reduce the selling price significantly which will improve the sales appeal considerably."    

"Additionally, we expect that the state-of the-art technology will result in more consistent tissue temperature data.  The Synergy Technology team understands medical device requirements and has the experience to expedite this important process for us," adds Holmes.

Synergy Technology, Inc.

For over 20 years, Synergy Technology has provided a cost-effective and flexible alternative to in-house staffing by providing deep knowledge, experience and skills in multiple design and engineering disciplines to assist clients with product design, product development and product life cycle management. Synergy Technology has served over 100 product-centric companies around the world, from start-up to global enterprises in industries that include analytical, medical, gaming, automotive, communications, consumer products and aerospace. Headquartered in Reno, NV.  www.synergytec.com

About Lifeline Biotechnologies

Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV.  The Company has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer.  Three patents are pending, one patent is issued and three clinical trials with over 650 participants have been completed. www.lbti.com

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

For more information, contact:

Jim Holmes, CEO 775-326-9614

Email: [e-mail]

 

 

SOURCE Lifeline Biotechnologies, Inc.

Copyright 2011 PR Newswire